Boehringer Ingelheim's Scovella Receives EMA CVMP Recommendation for Approval of Equine Metabolic Syndrome Treatment Following Re-examination
Scovella's Dramatic Reversal: Approval Recommended After June Rejection
During the regular meeting held from November 3 to 5, 2026, the Committee for Veterinary Medicinal Products (CVMP) under the European Medicines Agency (EMA) adopted a Positive Opinion for Marketing Authorisation for Boehringer Ingelheim's equine metabolic syndrome treatment 'Scovella (active ingredient: velagliflozin)'. This decision represents a complete reversal of the Negative Opinion issued during the June 2026 meeting, which had cited insufficient evidence regarding the benefit-risk balance of clinical data, following a formal Re-examination request by the applicant. The regulatory authority's shift in stance indicates that the additional evidence of efficacy and safety submitted under strict scrutiny satisfied veterinary medical necessity, demonstrating that the commercialization roadmap, previously delayed by regulatory risks, has returned to its intended course.
A Game-Changer for Equine Metabolic Syndrome and Laminitis Based on SGLT-2 Inhibition
Scovella is an oral liquid formulation developed as a Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitor that blocks glucose reabsorption in the equine kidney, aiming to improve hyperinsulinaemia in horses with Equine Metabolic Syndrome (EMS) that do not respond to dietary and exercise regimens. Hyperinsulinemia caused by Equine Metabolic Syndrome (EMS) is a key pathogenic mechanism for laminitis, a fatal foot disease that causes extreme pain and gait impairment, potentially leading to euthanasia. As direct approved treatment options were extremely limited beyond management through diet and exercise, the emergence of a targeted mechanism that fundamentally inhibits the risk of laminitis by lowering blood insulin levels brings about a paradigm shift in animal welfare and clinical practice.
First 'Restricted Market' Track Completion Under EU Regulation 2019/6
This CVMP recommendation for approval is a landmark first case to pass the authorization gateway under the 'Limited Market' exemption provision of the new European Union veterinary medicinal products regulation, Regulation (EU) 2019/6, which entered into force in 2022. The Limited Market system is a mechanism that allows early market entry by flexibly easing comprehensive clinical evidence requirements for specific diseases with small patient populations or high unmet medical needs. Through this approval recommendation, Boehringer Ingelheim has established a model precedent for overcoming regulatory uncertainty by combining data supplementation strategies with flexible regulatory tracks under stringent new regulations.
Preempting the High-Value Equine Healthcare Market and Commercial Impact
As the final official approval from the European Commission (EC) typically occurs within 67 days of the CVMP opinion adoption, Scovella is expected to be commercially launched across Europe in early 2027. This marks the expansion of animal SGLT-2 inhibitors—previously limited to feline diabetes, such as Elanco's Bexacat and Boehringer Ingelheim's Senvelgo—into the high-value equine treatment market for large animals. By securing a dominant position in the premium equine care market centered around the riding and racing industries in Europe, it is expected to significantly accelerate revenue growth and profitability enhancement for Boehringer Ingelheim's animal health division.
This CVMP approval recommendation (Approval stage) is a case of completely resolving regulatory risk by overturning the initial rejection from June 2024 through the re-examination process, providing an opportunity to preempt a dominant standard-of-care position in the approximately $1.57 billion global equine veterinary therapeutics market. In the short term, as the first product to pass the Article 23 Limited Market scheme under the EU Veterinary Medicinal Products Regulation (Regulation (EU) 2019/6), which came into force in 2022, it will serve as a benchmark for the authorization of subsequent new drugs. Furthermore, immediate cash flow generation for Boehringer Ingelheim through its early 2027 European commercial launch is assured. Unlike existing SGLT-2 inhibitors such as Elanco's Bexacat, which were confined to small animal diabetes treatment, this product expands the target disease area to large animal metabolic syndrome and the prevention of fatal laminitis, and is projected to monopolize the unmet demand in the global equine healthcare market, which reaches approximately $5 billion. In the mid-to-long term, by securing clinical evidence as a first-in-class drug in the hyperinsulinemia space where no approved treatments previously existed, it is anticipated that the company will enjoy unrivaled premium pricing power and high operating margins following future US FDA approval and within the sports horse care sector.